Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for LefT main Artery registry substudy).
Conrotto F, Scacciatella P, D'Ascenzo F, Chieffo A, Latib A, Park SJ, Kim YH, Onuma Y, Capranzano P, Jegere S, Makkar R, Palacios I, Buszman P, Chakravarty T, Mehran R, Naber C, Margey R, Leon M, Moses J, Fajadet J, Lefèvre T, Morice MC, Erglis A, Tamburino C, Alfieri O, D'Amico M, Marra S, Serruys PW, Colombo A, Meliga E. Conrotto F, et al. Among authors: fajadet j. Am J Cardiol. 2014 Jun 15;113(12):2007-12. doi: 10.1016/j.amjcard.2014.03.044. Epub 2014 Apr 1. Am J Cardiol. 2014. PMID: 24793677
Triple vessel stenting for triple vessel coronary disease.
Villegas B, Morice MC, Hernandez S, Choussat R, Dumas P, Lefevre T, Louvard Y, Loubeyre C, Fajadet J, Marco J. Villegas B, et al. Among authors: fajadet j. J Invasive Cardiol. 2002 Jan;14(1):1-5. J Invasive Cardiol. 2002. PMID: 11773686 Clinical Trial.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. Morice MC, et al. Among authors: fajadet j. N Engl J Med. 2002 Jun 6;346(23):1773-80. doi: 10.1056/NEJMoa012843. N Engl J Med. 2002. PMID: 12050336 Free article. Clinical Trial.
Percutaneous treatment of coronary subclavian steal syndrome.
Mulvihill NT, Loutfi M, Salengro E, Boccalatte M, Laborde JC, Fajadet J, Marco J. Mulvihill NT, et al. Among authors: fajadet j. J Invasive Cardiol. 2003 Jul;15(7):390-2. J Invasive Cardiol. 2003. PMID: 12840236
High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.
Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell ME; SCORE randomized trial. Grube E, et al. Among authors: fajadet j. J Am Coll Cardiol. 2004 Oct 6;44(7):1368-72. doi: 10.1016/j.jacc.2004.06.054. J Am Coll Cardiol. 2004. PMID: 15464315 Free article. Clinical Trial.
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E. Fajadet J, et al. Circulation. 2005 Mar 1;111(8):1040-4. doi: 10.1161/01.CIR.0000156334.24955.B2. Epub 2005 Feb 21. Circulation. 2005. PMID: 15723977 Free article. Clinical Trial.
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Fajadet J, et al. Circulation. 2006 Aug 22;114(8):798-806. doi: 10.1161/CIRCULATIONAHA.105.591206. Epub 2006 Aug 14. Circulation. 2006. PMID: 16908773 Clinical Trial.
Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial.
Valgimigli M, Dawkins K, Macaya C, de Bruyne B, Teiger E, Fajadet J, Gert R, De Servi S, Ramondo A, Wittebols K, Stoll HP, Rademaker TA, Serruys PW. Valgimigli M, et al. Among authors: fajadet j. J Am Coll Cardiol. 2007 Jan 30;49(4):431-41. doi: 10.1016/j.jacc.2006.06.081. Epub 2007 Jan 12. J Am Coll Cardiol. 2007. PMID: 17258088 Free article.
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Fajadet J, et al. Minerva Cardioangiol. 2007 Feb;55(1):1-18. Minerva Cardioangiol. 2007. PMID: 17287679 Clinical Trial. English, Italian.
269 results